New Delhi: India has told the US it won’t abstain from capping prices for more medical devices, regardless of pressure to rethink its stance after price controls on heart stents and knee implants spoilt the market for some US firms, sources familiar with the matter said.
India’s drug pricing authority is also pushing to bring three more devices used while treating heart ailments under the ambit of price controls as they are sometimes more expensive than the stent itself, showed a letter reviewed by Reuters.
India’s $5 billion medical device market has provided rich fishing grounds for US-based companies like Abbott Labs and Boston Scientific, but the prospect of price caps being extended to more products sent shivers through their ranks.
In September, the USTR wrote to Prime Minister Narendra Modi’s office and commerce minister Suresh Prabhu urging them “to not expand price controls to additional medical devices”, according to a copy of the letter seen by Reuters.
During a meeting last month, Indian officials told USTR Assistant Trade Representative Mark Linscott that India had decided against making any such commitment, a trade ministry official told Reuters on Tuesday. “This position will not change, it is within the right of the government of India (to impose price caps),” said the official, who declined to be named.
Mr Linscott “expressed concerns” with India’s stance during the meeting, another Indian trade official said.
Price controls form part of Modi’s broader agenda to improve India’s dilapidated public health system and boost affordability of treatment.
Equating high trade margins on some medical devices with “illegal profiteering”, the government last year capped prices of some high-end heart stents at around $450, compared to $3,000 charged earlier.
India’s National Pharmaceutical Pricing Authority has been pushing for more price controls. The regulator wrote to the health ministry asking for three other devices to be added to a list of products eligible for price controls.
